PhaseBio Expands Executive Management Team
October 24, 2019 16:01 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa. and SAN DIEGO, Calif., Oct. 24, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
PhaseBio Announces First Patient Dosed in Phase 2b Clinical Trial of PB2452 for Reversal of the Antiplatelet Activity of Ticagrelor
October 15, 2019 08:00 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa. and SAN DIEGO, Oct. 15, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
PhaseBio Announces Completion of Phase 2a Clinical Trial of PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor
September 24, 2019 16:01 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa. and SAN DIEGO, Sept. 24, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
Pharmacodynamics Evaluation of PhaseBio’s Novel Ticagrelor Reversal Agent Presented at ESC Congress 2019
September 03, 2019 08:00 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa. and SAN DIEGO, Sept. 03, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
PhaseBio Announces Presentation of PB2452 Data at ESC Congress 2019
August 26, 2019 08:00 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa. and SAN DIEGO, Aug. 26, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
PhaseBio Announces Receipt of Minutes of End-of-Phase 1 Meeting with the FDA and Alignment on a Single, Non-Randomized Phase 3 Trial to Support BLA Submission for PB2452
August 14, 2019 07:00 ET
|
PhaseBio Pharmaceuticals, Inc.
Clinical development plan and Accelerated Approval regulatory path confirmed Phase 3 trial to initiate in the first quarter of 2020 and intended to support both major bleeding and surgery...
PhaseBio Reports Second Quarter 2019 Financial Results and Recent Corporate Progress
August 13, 2019 16:01 ET
|
PhaseBio Pharmaceuticals, Inc.
Reported positive preliminary results from Phase 2a trial of PB2452 Received FDA Breakthrough Therapy designation for PB2452 Completed underwritten public offering of common stock that raised $46.3...
PhaseBio To Report Second Quarter 2019 Financial Results and Recent Corporate Progress on August 13, 2019
August 06, 2019 16:01 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa. and SAN DIEGO, Aug. 06, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
PhaseBio Added to Russell 2000® and 3000® Indexes
July 01, 2019 08:00 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa., and SAN DIEGO, Calif., July 01, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
PhaseBio Announces Positive Preliminary Results from Phase 2a Clinical Trial of PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor in Older and Elderly Subjects
June 17, 2019 16:01 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa. and SAN DIEGO, June 17, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...